Zinc in PDB 9nto: Structure of CAP9-Cdnd Complex Containing Ndg Modification

The structure of Structure of CAP9-Cdnd Complex Containing Ndg Modification, PDB code: 9nto was solved by D.R.Wassarman, P.Pfaff, J.A.Paulo, S.P.Gygi, K.M.Shokat, P.J.Kranzusch, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	43.15 / 2.15
Space group	P 21 21 2
Cell size a, b, c (Å), α, β, γ (°)	92.664, 58.219, 89.228, 90, 90, 90
R / Rfree (%)	20.5 / 23.2

The binding sites of Zinc atom in the Structure of CAP9-Cdnd Complex Containing Ndg Modification (pdb code 9nto). This binding sites where shown within 5.0 Angstroms radius around Zinc atom.
In total only one binding site of Zinc was determined in the Structure of CAP9-Cdnd Complex Containing Ndg Modification, PDB code: 9nto:

Zinc binding site 1 out of 1 in the Structure of CAP9-Cdnd Complex Containing Ndg Modification


Mono view


Stereo pair view

A full contact list of Zinc with other atoms in the Zn binding site number 1 of Structure of CAP9-Cdnd Complex Containing Ndg Modification within 5.0Å range: probe atom residue distance (Å) B Occ B:Zn201 b:30.0 occ:1.00 SG B:CYS169 2.3 30.3 1.0 SG B:CYS180 2.3 30.5 1.0 SG B:CYS177 2.3 33.0 1.0 SG B:CYS183 2.3 36.9 1.0 CB B:CYS169 3.2 29.8 1.0 CB B:CYS183 3.4 34.7 1.0 CB B:CYS180 3.4 32.5 1.0 N B:CYS177 3.5 36.5 1.0 CA B:CYS169 3.5 34.3 1.0 CB B:CYS177 3.6 34.9 1.0 N B:GLY178 3.8 38.8 1.0 CA B:CYS177 4.0 38.8 1.0 N B:CYS180 4.0 33.7 1.0 N B:GLU170 4.0 30.7 1.0 C B:CYS169 4.1 32.4 1.0 OG B:SER171 4.1 36.4 1.0 CA B:CYS180 4.3 33.0 1.0 C B:CYS177 4.3 36.0 1.0 N B:CYS183 4.3 34.3 1.0 N B:SER171 4.4 31.0 1.0 CA B:CYS183 4.4 36.6 1.0 CB B:SER171 4.5 32.2 1.0 C B:PRO176 4.5 37.2 1.0 CB B:PRO176 4.6 37.1 1.0 N B:SER179 4.6 37.0 1.0 CA B:GLY178 4.8 36.4 1.0 CA B:PRO176 4.8 37.4 1.0 O B:HOH377 4.8 38.2 1.0 N B:CYS169 4.8 33.4 1.0 C B:CYS180 4.9 37.0 1.0 O B:CYS180 4.9 33.3 1.0

D.R.Wassarman, P.Pfaff, J.A.Paulo, S.P.Gygi, K.M.Shokat, P.J.Kranzusch. Deazaguanylation Is A Nucleobase-Protein Conjugation Required For Type IV Cbass Immunity. Biorxiv 2025.
ISSN: ISSN 2692-8205
PubMed: 40236162
DOI: 10.1101/2025.04.06.647259